Protalix BioTherapeutics (PLX) Misses Q2 EPS by 15c
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.67 +1.91%
Revenue Growth %: -15.8%
Financial Fact:
NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED:: -0.07
Today's EPS Names:
PMCB, CULP, HURC, More
Revenue Growth %: -15.8%
Financial Fact:
NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED:: -0.07
Today's EPS Names:
PMCB, CULP, HURC, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.04), $0.15 worse than the analyst estimate of $0.11. Revenue for the quarter came in at $25.77 million versus the consensus estimate of $23.1 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- Goldman Sachs Downgrades Schindler Holding AG (SCHN:SW) (SHLAF) to Sell
- ADARx Pharmaceuticals files for proposed IPO
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
